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Bufadienolides are cytotoxic drugs that may form the basis for anticancer agents. Due to structural and
functional similarity to cardiotonic glycosides, application is restricted. We, therefore, investigated cor-
relation of their putative anticancer effects with inhibition of Naþ ,Kþpumps. The natural bufalin and
three derivatives were tested. The anticancer effects of the drugs were checked by observing their in-
hibitory effects on proliferation of rat liver cancer cells using MTT assay. Inhibition of Naþ ,Kþ-pump was
determined by measuring pump-mediated current of rat α1/β1 and α2/β1 Naþ ,Kþpumps expressed in
Xenopus oocytes.
All tested bufadienolides inhibited cell proliferation and Naþ ,Kþpump activity. An activity coefﬁcient
A¼100xIC50Na,K pump/IC50proliferation was used to describe drug effectivity as anticancer drug. Natural
bufalin exhibited lowest effectivity on cell proliferation, and also the A value for rat α1 isoform was the
lowest (0.08), the α2 isoform was much less sensitive (A¼1.00). The highest A values were obtained for
the BF238 derivative with A¼0.88 and 2.64 for the α1 and α2 isoforms, respectively. Therefore, we
suggest that search for bufalin derivatives with high anticancer effect and low afﬁnity for both
Naþ ,Kþpump isoforms may be a promising strategy for development of anticancer drugs.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bufadienolides are natural steroids originally extracted from
Chan Su, a traditional Chinese remedy found in skin and parotid
venom glands of toads (Bufo) as well as in plants [1]. The drugs
have been recognized as effective antitumor agents [1–4]. Because
of some structural similarity to digitalis glycosides, they also act as
potent cardiotonic steroids [5,6]. The application of bufadienolides
in cancer treatment is, therefore, restricted by their side effects on
the Naþ ,Kþpump (also known as Naþ ,Kþ-ATPase or Naþ pump),
the most essential membrane protein of nearly all animal cells.B.V. This is an open access article u
side; BF238, Bufalin-3-Yl [3-
-Yl [3-(methylamino)propyl]
yltetrazolium bromide; ORi,
formed by Α1 and Β1 sub-
1 subunits; TEA‐Cl, Tetra-
e-University, Frankfurt Max-
arz).Bufalin is the major active component of the Bufo venum and
exhibits cytotoxic effects against a large variety of tumor cells (see
e.g. [7,8]) and has also been introduced in clinical cancer therapy
[9,10]. The main problem for its clinical application is the high
cardiac toxicity of this drug [5,11]. To minimize such side effects,
bufalin-loaded carriers have been developed for tissue-speciﬁc
targeting [12,13]. Another strategy might be to develop derivatives
of the natural bufalin with relatively weaker inhibition on the
Naþ ,Kþpump and stronger inhibition on cell proliferation.
In our experiments we used bufalin and several representative
bufalin derivatives to answer the question whether the cytotoxic
effects are correlated with the effects on Naþ ,Kþpumps, or whe-
ther there exists a drug with high anticancer but comparably low
cardiotonic activity, which may then form the basis for the de-
velopment of new anticancer drugs.
We investigated the effects of the naturally derived bufalin. In
addition, we screened three synthesized bufalin derivatives with
respect to their inhibitory effect on proliferation of rat cancer cells
and inhibition of rat Naþ ,Kþpumps:
Bufalin-3-yl [3-(1h-imidazol-1-yl)propyl]carbamate(BF238),nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Effect of bufadienolides on rat RH-35 and human HeLa cells described by IC50 values for 50% inhibition of cell proliferation. Data represent averages of 3 independent
experiments þ SEM.
Bufadienolide Structure Cell proliferation
RH-35 IC50 (lM) HeLa IC50 (lM)
Bufalin 257.0717.5 23.372.4 (103)
Bufalin-3-MeON-arabinopyranoside (BAP) 67.2710.4 26.872.3 (103)
Bufalin-3-yl [3-(1h-imidazol-1-yl)propyl]carbamate (BF238) 37.473.1 47.372.4 (103)
Bufalin-3-yl [3-(methylamino) propyl]carbamate (BF601) 30.875.0 115.074.4 (103)
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Bufalin-3-yl [3-(methylamino)propyl]carbamate(BF601).
For comparison, the structures of the bufadienolides we used in
our investigation are shown in Table 1.
The catalytically functional subunit of Naþ ,Kþpump is the α
subunit, containing the binding sites for ATP, the transported ca-
tions and also cardiac steroids. The glycosylated auxiliary β sub-
unit is needed for proper folding and insertion of the pump mo-
lecule into the cell membrane [14–19]. In rat cardiac muscle the α1
and α2 subunits are the dominating isoforms, the α3 subunit is
only detected at the neonatal stage [20,21]. Pumps with α1 sub-
unit are found ubiquitous and are considered as dominating
Naþ ,Kþpumps with housekeeping function. Inhibition of
Naþ ,Kþpump, particularly the α2/β1 pump, by cardiac steroids
leads to prolongation of the cardiac action potential and an in-
crease in intracellular Naþ , which in turn decreases the driving
force for the Naþ ,Ca2þexchanger and results in elevation of in-
tracellular Ca2þ . As a consequence, contractility of the working
cardiac myocyte is strengthened [22–28]. To investigate to which
extend the bufadienolides may exhibit cardiotonic effects, we
compared the effects of the drugs on the activity of rat α1/β1
(Rα1/β1) and α2/β1 (Rα2/β1) Naþ ,Kþpumps expressed in the
model system Xenopus oocyte. Since the oocytes express en-
dogenous Naþ pumps, these pumps also had to be characterized
with respect to their sensitivity to the drugs, and the respective
signals had to be subtracted from the total pump-current signal.
Pump activities were monitored by measuring the electrogenic
current mediated by the pumps under voltage clamp [29–31].
The aim of our study was to ﬁnd out whether cytotoxicity can
be correlated to pump inhibition, or whether there exists a bufalinderivative with high anticancer effect, but relatively low effect on
activity of pumps.2. Materials and methods
2.1. Cell culture
The RH-35 rat liver cancer cell line was obtained from Cell
Resource Center of Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences (Shanghai, P.R. China). Cells were
cultured in DMEM (Life Technologies, Gaithersburg, MD, USA) with
1.5 g/L sodium bicarbonate plus 10% fetal bovine serum. Anti-
biotics added were 100 units/mL penicillin and 100 μg/mL strep-
tomycin (Invitrogen, Karlsruhe, Germany).
2.2. MTT assay for inhibitory effects on cell proliferation
The inhibitory effects of bufalin and its derivatives on cancer
cell proliferation was determined by MTT assay, a tetrazolium-
based colorimetric assay, as reported before [32]. Brieﬂy, cells were
plated in 96-well ﬂat-bottomed plates at density of 1103 cells/
well in the complete medium and incubated overnight. Then,
media were changed to fresh media containing the various
amounts of the respective drug for 72 h. At the end of the in-
cubation period, 20 μL of the dye 3, [4,5-dimethylthiazol-2-yl-]
diphenyltetrazolium bromide (MTT, 5 mg/mL), was added to each
well, and the plates were incubated for 3 h at 37 °C. Thereafter,
100 μL of lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N,
N-dimethylformamide, containing 0.5% [v:v] 80% acetic acid and
Fig. 1. Dependence of viability of RH-35 cells on concentration of bufalin (open
squares) and BF238 (open circles). Data represent averages þ SEM (N¼3). Dashed
lines are approximations of euq. 1 with n¼1, Y0¼1, yielding IC50 values of 257.0 and
37.4 mM for bufalin and BF238, respectively.
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(16 h). Cell viability was evaluated by measuring the mitochon-
drial-dependent conversion of the yellow tetrazolium salt MTT to
purple formazan crystals by metabolic-active cells. The optical
density (proportional to the number of live cells) was assessed
with a Microplate Reader Bio-Rad 550 (Bio-Rad Laboratories,
Hercules, CA, USA) at 570 nm. Each experiment was performed in
triplicate. Results of three independent experiments were used for
statistical analysis. IC50 values (half-maximum inhibitory con-
centration) were calculated by the Logit method [32].
2.3. Oocytes
Females of the clawed toad Xenopus laevis (purchased from
Maosheng Bio-Technology Com., Shanghai, China) were anaes-
thetized in a bath medium containing 1 g/L tricaine (Sandoz, Basel,
Switzerland) and kept on ice. Parts of ovary were removed and
treated with 0.5 or 0.25 mg/mL collagenase (Sigma) for 2–4 h, or
overnight, respectively. Full-grown prophase-arrested oocytes
were selected for experiment. For expression of rat pumps, cRNA
encoding rat α1 or α2 isoform of the Naþ ,Kþpump together with
rat β1 subunit were injected into oocytes. To minimize com-
plexation of endogenous Xenopus α subunit with rat ß1 subunit
(see [33] cRNA of rat α and ß1 subunits was injected at a weight
ratio of 2/1(20 ng in total). Uninjected cells served as controls. The
oocytes were incubated for expression for 2 days at 2071 °C in
oocyte Ringer's solution (ORi, see 2.7 solutions) with added 70 mg/
L gentamycin. Experiments were performed at room temperature
(24–26 °C).
2.4. cRNA preparation
Constructs encoding full-length rat α1 (P06685) and α2
(P06686), as well as ß1 (P07340) subunits of the Naþ ,Kþpump
were kindly provided by Dr. G. Schmalzing and propagated in
JM109 bacteria. Capped cRNAs were synthesized in vitro using the
mMESSAGE mMACHINE SP6 kit (Ambion, USA). A Nanophot-
ometer P-Class (Implen, Germany) was used to check the quality
and quantity of cRNA.
2.5. Voltage-clamp experiments
Electrophysiological experiments were performed by conven-
tional two-electrode voltage clamp using Turbo TEC 03X with
CellWorks software (NPI electronic, Tamm, Germany). For detect-
ing Naþ ,Kþpump-mediated currents, oocytes were preloaded
with Naþ [31] by incubation in Naþ-loading solution for 30 min
(see solutions); before experiment the cells were kept at least for
20 min in post-loading solution (see solutions). Steady-state cur-
rents were recorded from the Naþ-loaded oocytes at the end of
200-ms voltage pulses from 150 up to þ30 mV in 10-mV in-
crements that were applied from a holding potential of 60 mV.
The difference between the steady-state currents in the presence
of extracellular Kþand in its absence was used as a measure of the
pump-mediated currents [31]. The external test solutions were
similar to ORi solution (see 2.7 Solutions) but contained BaCl2 and
tetraethylammonium chloride (TEA-Cl) to reduce other
Kþ-sensitive currents. A remaining contribution of non-pump-
mediated current (about 10%) was subtracted for ﬁnal data
analysis.
2.6. Bufadienolides
Bufalin was isolated and puriﬁed from Chan Su as reported
before [34]. Derivatives of bufalin such as BAP, BF238 and BF601
were obtained by structure modiﬁcation of bufalin. The structuresof bufalin and its derivatives are shown in Table 1.
Stock solutions of 1 or 100 mM were prepared in DMSO and
diluted to ﬁnal concentration in the test solution. DMSO con-
centrations in the test solution were always below 0.1% which was
without effect on the pump-mediated currents.
2.7. Solutions
The standard ORi (Oocyte Ringer's) solution was composed of
(in mM): 90 NaCl, 2 KCl, 2 CaCl2 and 5 MOPS (adjusted to pH
7.4 with Tris). Test solutions contained (in mM) 0 or 2 KCl, and 90
NaCl, 5 BaCl2, 20 TEA-Cl and 5 MOPS (adjusted to pH 7.4 with Tris).
Naþ-loading solution was composed of (in mM) 110 NaCl, 2.5
Naþ-citrate and 5 MOPS; and post-loading solution contained (in
mM) 100 NaCl, 1 CaCl2, 5 MOPS, 5 BaCl2 and 20 TEA-Cl (both so-
lutions adjusted to pH 7.6 with Tris).
2.8. Data analysis
All measured data are represented as averagesþSEM (standard
error of the mean) of N experiments. To estimate dependency of
cell viability and Naþ ,Kþ-pump activity on drug concentration Hill
equation was ﬁtted to the normalized data using Origin software:
=
+ [ ] ( )
Y
IC
IC drug 1
n
n n
50
50
with drug concentration [drug], IC50 the drug concentration for
50% inhibition, and Hill coefﬁcient n.3. Results
3.1. Inhibitory effect on cancer cell proliferation
To determine inhibitory effects of the bufadienolides on cancer
cell proliferation, a colorimetric tetrazolium (MTT) assay was ap-
plied to the rat liver cancer cell line RH-35. Fig. 1 shows the de-
pendency of inhibition of cell proliferation on concentration of
bufalin and the bufalin derivative BF238. The IC50 value for bufalin
was with 257.0 mM nearly one order of magnitude higher than the
value for BF238 with 37.4 mM.
IC50 values were also estimated for BF601, with about 30.8 mM
Table 2
IC50 values for inhibition of Naþ ,Kþpump current at 60 mV. The values are gi-
venþerrors of the ﬁtted IC50 values to the respective set of data presenting
averages of 5–6 oocytes were obtained by least-squares ﬁts of Eq. (1) to the data
shown in Figs. 2, 3, and 4, respectively.
Bufadienolide Endogenous pump Rα1/β1 pump Rα2/β1 pump
IC50 (lM) IC50 (lM) IC50 (lM)
Bufalin 0.063þ0.012 0.215þ0.069 2.558þ1.154
BAP 0.047þ0.007 0.063þ0.015 0.110þ0.015
BF238 0.021þ0.005 0.329þ0.083 0.987þ0.322
BF601 0.101þ0.026 0.107þ0.027 0.283þ0.045
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results are summarized in Table 1, listed from top to bottom from
the lowest to highest inhibitory effect on cell proliferation.
Table 1 also lists corresponding IC50 value for inhibition of cell
proliferation of the human HeLa cancer cell line. HeLa cells are by
about 3 orders of magnitude more sensitive than the rat RH-35
cells.
3.2. Expression of Rα1/β1 and Rα2/β1 in Xenopus oocytes
To extract pump-mediated current from total membrane cur-
rent, we blocked Kþ-selective channels, so the current, which can
be activated by extracellular Kþunder these conditions, can be
considered to represent predominantly pump-mediated current
[31]. The voltage dependencies of Kþ-sensitive current in oocytes
injected with the respective cRNA are shown together with those
of uninjected cells in Supplemental Fig. 1. The increase in pump
current reﬂects the additional activity of the exogenous rat pumps.
Exogenous pump current is about 3–4 times larger than the en-
dogenous pump current.
3.3. Sensitivity of endogenous pump to bufadienolides
Though our focus was on the effects of bufadienolides on the
rat Rα1/β1 and Rα2/β1 pumps, we ﬁrst investigated the effects on
the endogenous pumps of Xenopus oocytes, which was necessary
for calculating the current generated by the expressed rat pumps.
Endogenous pump-mediated current was determined as
Kþ-sensitive current in uninjected control oocytes. As for inhibi-
tion of cancer cell proliferation, we analyzed in detail the effects of
bufalin and BF238. Fig. 2A shows an example of averaged current-
voltage dependencies from oocytes in the absence and presence of
0.05 mM bufalin, which gave nearly 50% inhibition of the pump
current by this natural product of the Bufo venom over the entire
voltage range. A more detailed analysis revealed only slight vol-
tage dependency. At the same concentration of 0.05 mM, BF238
exhibited slightly more inhibition (Fig. 2B). The dependency of
pump inhibition on bufalin and BF238 concentration is illustrated
for the pump current at 60 mV in Fig. 2C. The IC50 values for 50%
inhibition could be estimated to about 0.06 mM and 0.02 mM, re-
spectively, by ﬁtting Eq. (1) to the data. Because the other drugs
also exhibited no signiﬁcant voltage dependency of current in-
hibition, we screened the concentration dependence of the two
other drugs, BAP and BF601, also at 60 mV. The inhibition could
be described by IC50 values of about 0.05 and 0.10 mM for BAP and
BF601, respectively (Table 2). The BF238 derivative seems to be
slightly more effective in inhibiting the endogenous Naþ ,Kþpump
than the natural bufalin as well as the two other derivatives (seeFig. 2. Dependence of endogenous Naþ ,Kþpump current on concentration of bufadienol
application of 0.05 mM bufalin (open squares) and 0.05 mM BF238 (open circles), respecti
inhibition of endogenous Naþ ,Kþpump current by bufalin (open squares) and BF238 (op
ﬁts of euq. 1 with n¼0.81, yielding IC50 values of 0.063 and 0.021 mM, respectively (comTable 2).
To evaluate the effect of bufadienolides on the rat pumps, the
contribution of endogenous pumps to total pump-mediated cur-
rent was always subtracted using the above data for the results
illustrated below.
3.4. Sensitivity of Rα1/β1 pump to bufadienolides
Rα1/β1 is known to be quite insensitive to cardiac glycosides
[35]. Our data also show that sensitivity of the Rα1/β1 pump to
bufadienolides is indeed signiﬁcantly lower than that of the en-
dogenous Xenopus pump isoform. At 0.05 mM bufalin the en-
dogenous pump was inhibited by 50%, but Rα1/β1 activity was less
affected at this concentration (compare Figs. 2A and 3A). The
BF238 even hardly affected Rα1/β1 pump current at 0.05 mM, and
only 0.50 mM exhibited slightly more than 50% inhibition (see
Fig.3B). For analyzing IC50 values we subtracted the contribution of
endogenous current component from total pump-mediated cur-
rent before calculating the efﬁciency of inhibition by bufadieno-
lides for the expressed Rα1/β1 pump. Fig. 3C shows the de-
pendency of the Rα1/β1 pump current at 60 mV on bufalin
concentration, which was with an IC50 value of 0.215 mM by a
factor of 3 less effective than for the endogenous Xenopus pump;
BF238 was by more than an order of magnitude less effective with
an IC50 value of 0.329 mM (Fig. 3B, compare Table 2). The other two
screened drugs, BF601 (IC50¼0.107 mM) and BAP (IC50¼0.063 mM)
were also less effective in inhibiting the Rα1/β1 pump than the
endogenous pump, but more effective than the natural bufalin and
BF238 (see Table 2).
3.5. Sensitivity of Rα2/β1 pump to bufadienolides
Also for the Rα2/β1 pump concentrations of bufalin and BF238
in the 0.05 mM range were not sufﬁcient to produce clear inhibi-
tion, and 0.50 mM needed to be applied (see Fig. 4A and B). Forides. (A, B) Current-voltage dependencies in the absence (ﬁlled squares) and during
vely. Data represent averages of N¼5 oocytes þ SEM. (C) Concentration-dependent
en circles). Data represent averages of 5–10 measurements þ SEM. Dashed lines are
pare dashed lines).
Fig. 3. Dependencies of Naþ ,Kþpump current in oocytes with additionally expressed rat Rα1/ß1 pumps. (A, B) Current-voltage dependencies in the absence (ﬁlled squares)
and during application of 0.05 mM bufalin (open squares) and 0.05 mM BF238 (open circles), respectively. Data represent averages of N¼6 oocytes þ SEM. (C) Concentration-
dependent inhibition of endogenous Naþ ,Kþpump current by bufalin (open squares) and BF238 (open circles). Data represent averages of 5–10 measurements þ SEM. Solid
lines are ﬁts of euq. 1 with n¼0.8, yielding IC50 values of 0.215 and 0.329 mM, respectively (compare dashed lines).
Table 3
Efﬁcacy of bufadienolides as anticancer drugs expressed by the efﬁciency coefﬁ-
cient A determined by Eq. (2) for RH-35 cells and the respective rat Naþ ,Kþpump
from the data given in Tables 1 and 2.
Bufadienolide Rα1/β1 pump Rα2/β1 pump
Bufalin 0.08 1.00
BAP 0.10 0.16
BF238 0.88 2.64
BF601 0.35 0.92
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of the endogenous Naþ ,Kþpump from total Kþ-sensitive current
as described above. The data are shown in Fig. 4C for the current at
60 mV. The calculated IC50 values are listed in Table 2 again
together with the values for the two other screened drugs BAP and
BF601. Except for BAP, all tested drugs were signiﬁcantly less ef-
fective in inhibition of the Rα2/β1 pump than the Rα1/β1 pump.
The IC50 value of bufalin for Rα2/β1 of more than 2 mM was by an
order of magnitude higher than the value for Rα1/ß1. The esti-
mated IC50 value with 0.11 mM for BAP was slight higher than the
value for Rα1/ß1 (Table 2).4. Discussion
Cardiotonic steroids, including bufalin, are used for many years
in treatment of congestive heart failure by strengthening myo-
cardial contractility [7,36]. These drugs have also been suggested
as candidate for the development of anticancer drugs (see e.g.
[37,38]). The aim of our work was to investigate whether antic-
ancer effects can be correlated to Naþ ,Kþpump inhibition, or
whether a bufadienolide can be developed that is highly effective
as anticancer agent, but is less potent as inhibitor of Naþ ,Kþpump.
To express such effectivity, we determined efﬁciency coefﬁ-
cients A as the ratio of the IC50 values:
= *
( )
A
IC
IC
100
2
Na Kp mp
proliferation
50
, u
50
The A values calculated on the basis of the data shown in
Tables 1 and 2 are presented in Table 3. Interestingly, the Rα2/β1Fig. 4. Dependencies of Naþ ,Kþpump current in oocytes with additionally expressed rat
and during application of 0.05 and 0.5 mM bufalin (open squares and circles) and 0.05 and
þ SEM. (C) Concentration-dependent inhibition of endogenous Naþ ,Kþpump current b
measurements þ SEM. Solid lines are ﬁts of euq. 1 with n¼0.8, yielding IC50 values ofpump was less sensitive to each of the tested drugs than the Rα1/
β1 pump (Table 2). This is in contrast to the effect of the cardio-
tonic steroid ouabain, which is known to be highly insensitive to
inhibit Rα1/β1 pump. Naþ ,Kþpumps with the α1 subunit are
found in nearly all animal cells, and seem to serve as the major
housekeeping pump while pumps with α2 subunit exhibit tissue-
speciﬁc distribution and are found predominately in muscle and
nerve cells [26].
The pump with α1 subunit has been demonstrated to be in-
volved in various signaling pathways [39] and is highly expressed
in tumor tissue [40]. There are two pools of Naþ ,Kþ-ATPase within
the plasma membrane: the classical pool of the enzyme acts as
energy transducing Naþ ,Kþpump; the other pool is restricted to
the caveolae, forming the “Naþ/Kþ-ATPase signalosomes” as sig-
nal-transducing enzyme [41]. Generally, the anti-cancer effects of
cardiac steroids were thought to be mainly based on binding to the
Naþ/Kþ-ATPase signalosome [42]. The much lower IC50 values of
inhibition of Naþ , Kþpump current may be attributed to the fact
that inhibition of Naþ pump current by bufadienolides is not di-
rectly associated with the binding to Naþ ,Kþ-ATPaseRα2/ß1 pumps. (A, B) Current-voltage dependencies in the absence (ﬁlled squares)
0.5 mM BF 238 (open circles and rhombs). Data represent averages of N¼6 oocytes
y bufalin (open squares) and BF238 (open circles). Data represent averages of 5–10
2.558 and 0.987 mM, respectively (compare dashed lines).
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of cell proliferation. Experiments on genetically modiﬁed mice
demonstrated that, instead of mediating inotropic effects (as ex-
pected for the α2 isoform of the pump), the α1 isoform may play a
different role and mediate toxic effects [22]. In addition, elevated
α1 expression has been reported in some malignant cells [43,44].
Such features may lead to higher sensitivity of cancerous cells to
bufadienolides than that of normal cells; therefore, the strategy of
screening bufadienolides as candidate for anti-tumor drugs is
feasible. The α2/β1 pump is well known to govern the length of
the cardiac action potential and controls Ca2þ inﬂux through the
Naþ ,Ca2þexchanger via intracellular Naþ [25,27,28,45]. Therefore,
the low sensitivity of α2/β1 pump against the bufadienolides
makes them less harmful as cardiotonic drugs, but good candi-
dates for developing anticancer drugs.
Among the tested drugs, the one with the lowest efﬁcacy in
inhibiting cell proliferation was the natural bufalin with an IC50
value of 257.0 μM (Table 1). Though the rat pumps were also quite
insensitive to bufalin compared to the other drugs (see Table 2),
the efﬁciency coefﬁcients A for bufalin was with 0.08 the lowest
for Rα1/β1, for Rα2/β1 the value turned out to be with 1.0 in an
intermediate range making this natural bufadienolide suitable as a
basis for developing anticancer drug. BAP exhibited the low efﬁ-
ciency for both isoforms, while BF601 was with A¼0.35 and 0.92,
for Rα1/β1 and Rα2/β1, respectively, quite effective (Table 3).
The inhibitory effect of BF238 on cancer cell proliferation, with
an IC50 value of 37.4 mM is slightly less cytotoxic than BF601.
However, both Rα1/β1 and Rα2/β1 are relatively insensitive to this
drug, so the A value for BF238 turned out to be 0.88 for Rα1/β1
and 2.64 for Rα2/β1, which makes BF238 the best candidate for
further research. Our results of MTT assay are not sufﬁcient to
prove the cytotoxicity effects and mechanism of action of the
compounds. Unpublished data from our collaborators showed that
the effects and mechanisms of cytotoxicity of bufadienolides
might be similar. In cells treated with bufadienolides, apoptosis
and change in signal pathway such as inhibition of PI3K/Akt could
be observed (Feng et al. unpublished).
Our results indicate no direct correlation between inhibition of
cell proliferation and pump inhibition. Therefore, an additional
mechanism, like the interaction with the signalosome function,
might favor the inhibitory effect of the BF238 on cancer cell pro-
liferation. Interestingly, BF238 is characterized by an imidazole
residue. A recent study [46] showed that imidazole can inhibit
autophagy ﬂux and induce apoptosis on HEC-1B, a human en-
dometrial adenocarcinoma cell line, and provided the possible
mechanisms of imidazole and its derivatives acting as antitumor
drugs. Although we do not have data to prove it yet, the side chain
imidazole group in BF238 may improve the inhibitory effect on cell
proliferation.
Previous studies have shown that the Na pumps from different
species vary in the sensitivity to cardiac glycosides [47,48], We also
examined the inhibition of cell proliferation by the above bufa-
dienolides on the human HeLa cell line, which seems to be much
more sensitive to the bufadienolides than the rat cancer cells
(preliminary data are added to Table 1). The difference in IC50
values of bufadienolides in inhibiting proliferation of RH-35 cells
or HeLa cells may be related to different sensitivities of those two
cell species [49]. The sensitivity of human HeLa cells to the bufa-
dienolides with respect to cell proliferation was opposite to that of
rat RH-35 cells though not as pronounced as in the rat cells. To
judge on the applicability of bufadienolides as anticancer drugs in
human, corresponding experiments on inhibition of human α1
andα2 pumps will be needed. Thus, high effectivity of BF238 on
the rat system may not be readily transferred to human. However,
our data indicate that proper modiﬁcation of bufalin may increase
anticancer effectivity of derivatives and, nevertheless, reduce theirinhibition of Naþ , Kþpumps, which means having higher potential
as anticancer agent with less side effects. Therefore, additional
bufalin derivatives need to be screened in the future study, and the
investigations need to be extended to human cancer cells and
human Naþ ,Kþpumps. We, in particular, suggest BF238 with an
imidazole residue as a basis for further anticancer drug
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